Key facts
- It has raised $59.2M; the latest was Accelerator/Incubator in Jun 2024.
- Notable investors include SOSV, New Enterprise Associates, Abstract Ventures, IndieBio, DCVC — 40 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 40 names
- ·Watchlist + deal alerts for Catalog (Biotechnology)
- ·The full record, as it builds
Funding rounds
No funding rounds for Catalog (Biotechnology) are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Catalog (Biotechnology)
Developer of a data conversion and storage platform designed to offer the next generation of digital data archives. The company's platform facilitates the encoding of data and information into deoxyribonucleic acid (DNA) format and makes it economically attractive to use DNA as the major medium for the long-term archival of data, enabling customers to store digital information in DNA molecules.
- Sector
- Healthcare
- HQ
- Boston, MA, United States
- Founded
- 2016
- Employees
- 37
- Website
- catalogdna.com/
- Ownership
- Privately Held (backing)
Catalog (Biotechnology) doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Catalog (Biotechnology) shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Catalog (Biotechnology) in its N-PORT filings yet. We sweep new filings monthly.